INDICATIONS AND USAGE
Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms:
Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae.
Respiratory tract infections caused by
Mycoplasma pneumoniae.
Lymphogranuloma venereum caused by
Chlamydia trachomatis.
Psittacosis (Ornithosis) due to
Chlamydia psittaci.
Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence.
Chlamydia trachomatis
Inclusion conjunctivitis caused by
Chlamydia trachomatis.
Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or
Ureaplasma urealyticum
Chlamydia trachomatis.
Relapsing fever due to
Borrelia recurrentis.
Chancroid caused by
Haemophilus ducreyi.
Plague due to
Yersinia pestis.
Tularemia due to
Francisella tularensis.
Cholera caused by
Vibrio cholerae.
Campylobacter fetus infections caused by Campylobacter fetus.
Brucellosis due to species (in conjunction with streptomycin).
Brucella
Bartonellosis due to
Bartonella bacilliformis.
Granuloma inguinale caused by
Calymmatobacterium granulomatis.
Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:
Escherichia coli.
Enterobacter aerogenes.
species.
Shigella
species.
Acinetobacter
Respiratory tract infections caused by
Haemophilus influenzae.
Respiratory tract and urinary tract infections caused by species.
Klebsiella
Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
Upper respiratory tract infections caused by .
Streptococcus pneumoniae
Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.)
Staphylococcus aureus.
When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections:
Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections.
Neisseria gonorrhoeae
Infections in women caused by .
Neisseria gonorrhoeae
Syphilis caused by subspecies
Treponema pallidum
pallidum.
Yaws caused by subspecies
Treponema pallidum
pertenue.
Listeriosis due to
Listeria monocytogenes.
Anthrax due to .
Bacillus anthracis
Vincents infection caused by
Fusobacterium fusiforme.
Actinomycosis caused by
Actinomyces israelii.
Infections caused by species
Clostridium
.
In acute minocycline may be a useful adjunct to amebicides.
intestinal amebiasis,
In severe minocycline may be useful adjunctive therapy.
acne,
Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high.
Neisseria meningitidis
Oral minocycline is not indicated for the treatment of meningococcal infection.
Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by
Mycobacterium marinum.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.